Proteomics Heart Disease Jennifer Van Eyk, Ph.D. | Cedars-Sinai

Proteomics Heart Disease Jennifer Van Eyk, Ph.D. | Cedars-Sinai


Here at Cedars-Sinai we’re changing
medicine and we’re doing that two ways. The first way is to try to make drugs to
be more on target. If we’re more on target than we can reduce side effects
and we can also make sure that we’re getting the right drug to the right
person. The second part that we’re doing is we’re making diagnostic markers,
diagnostic markers that will help us to be able to ensure that we understand
your disease and to make sure we get the right drug to you. So what’s so exciting
about the technology that we use is that we’re able to monitor proteins
regardless of what disease that we’re looking at. So, my own passions and
cardiovascular disease and heart disease and women’s heart disease but to also be
able to use these technologies in these approaches across many questions in
medicine. The way that we do this is to be able to monitor and quantify the
proteins in yourself. Not all of them but many many of the proteins thousands of
them. The fundamental essence of the cell is really the proteins and by being able
to monitor and quantify the proteins and all their modified forms, we’re able to
figure out when you have a disease what’s gone wrong and then target that
specific set of proteins that are not acting properly and fix them by using
specific drugs.